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Abstract
OBJECTIVE: To assess prospectively the effect of benchmarking on quality of
primary care for patients with type 2 diabetes by using three major modifiable
cardiovascular risk factors as critical quality indicators. RESEARCH DESIGN
AND METHODS: Primary care physicians treating patients with type 2 diabetes in
six European countries were randomized to give standard care (control group) or
standard care with feedback benchmarked against other centers in each country
(benchmarking group). In both groups, laboratory tests were performed every 4
months. The primary end point was the percentage of patients achieving preset
targets of the critical quality indicators HbA1c, LDL cholesterol, and systolic
blood pressure (SBP) after 12 months of follow-up. RESULTS: Of 4,027 patients
enrolled, 3,996 patients were evaluable and 3,487 completed 12 months of follow-
up. Primary end point of HbA1c target was achieved in the benchmarking group
by 58.9 vs. 62.1% in the control group (P = 0.398) after 12...
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OBJECTIVEdTo assess prospectively the effect of benchmarking on quality of primary care
for patients with type 2 diabetes by using three major modiﬁable cardiovascular risk factors as
critical quality indicators.
RESEARCH DESIGNANDMETHODSdPrimary care physicians treating patients with
type 2 diabetes in six European countries were randomized to give standard care (control group)
or standard care with feedback benchmarked against other centers in each country (benchmark-
ing group). In both groups, laboratory tests were performed every 4 months. The primary end
point was the percentage of patients achieving preset targets of the critical quality indicators
HbA1c, LDL cholesterol, and systolic blood pressure (SBP) after 12 months of follow-up.
RESULTSdOf 4,027 patients enrolled, 3,996 patients were evaluable and 3,487 completed 12
months of follow-up. Primary end point of HbA1c target was achieved in the benchmarking
group by 58.9 vs. 62.1% in the control group (P = 0.398) after 12 months; 40.0 vs. 30.1%
patients met the SBP target (P , 0.001); 54.3 vs. 49.7% met the LDL cholesterol target (P =
0.006). Percentages of patients meeting all three targets increased during the study in both
groups, with a statistically signiﬁcant increase observed in the benchmarking group. The per-
centage of patients achieving all three targets at month 12 was signiﬁcantly larger in the bench-
marking group than in the control group (12.5 vs. 8.1%; P , 0.001).
CONCLUSIONSdIn this prospective, randomized, controlled study, benchmarking was
shown to be an effective tool for increasing achievement of critical quality indicators and poten-
tially reducing patient cardiovascular residual risk proﬁle.
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The prevalence of type 2 diabetes isstill rising; the ﬁfth edition of the Di-abetes Atlas estimates that there were
366 million people worldwide with dia-
betes in 2011 (1), an increase from the
285 million cited in the 2010 edition
(2). Management of patients with type 2
diabetes is complex because of multiple
priorities; its goal is to control not only
glycemia but also the other modiﬁable
risk factors for microvascular and macro-
vascular disease, as well as to prevent and
manage the related complications. For ef-
fective intervention, treatment needs to
be both multifactorial in approach and
tailored to the individual patient. Studies
have shown that cardiovascular disease
risk in type 2 diabetes was reduced by
control of key modiﬁable variables such
as HbA1c as a measure of chronic hyper-
glycemia (3), blood pressure (BP) (4,5),
and LDL cholesterol (6–8). The picture
is less clear-cut, however, with respect
to the risk-beneﬁt ratio of achieving a
HbA1c target level ,7% (53.0 mmol/mol).
Indeed, some studies have shown that pre-
vention of macrovascular events did not
signiﬁcantly improve if more stringent
HbA1c targets ,6.5% (47.5 mmol/mol)
were met (9,10).
Despite the availability of extensive
guidelines for the treatment of type 2
diabetes, there are gaps in knowledge,
attitude, and practice, for both patients
and physicians that are proving difﬁcult
to close (11). New strategies that have
been shown to help patients meet key tar-
get goals and improve clinical outcomes
are currently being investigated. One of
the approaches that may drive improve-
ment in quality of care is benchmarking.
Benchmarking in the clinical setting typ-
ically includes feedback on the perfor-
mance of a patient or physician, which
is ranked against that of a peer group.
Very few randomized, controlled trials
of benchmarking for type 2 diabetes in
primary care have been reported, and
the effectiveness of this approach is as
yet undetermined (12–14).
The OPTIMISE (OPtimal Type 2 dI-
abetes Management Including bench-
marking and Standard trEatment) study
was initiated (15) to assess prospectively
in a randomized, controlled trial the effect
of benchmarking on the quality of pri-
mary care for patients with type 2 diabetes
and its impact on achieving preset targets.
Baseline results from theOPTIMISE study
demonstrated that target achievement for
three critical quality indicators of vascular
risk was suboptimal in a primary care set-
ting (16). The results of the OPTIMISE
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study through 12months of follow-up are
presented here.
RESEARCH DESIGN AND
METHODSdThe OPTIMISE study
is registered at clinicaltrials.gov
(NCT00681850). This study was per-
formed in accordancewith the Declaration
of Helsinki, the International Conference
on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals
for Human Use (ICH)/Good Clinical
Practice, and applicable regulatory re-
quirements. All protocols and study
documentation were approved by the
appropriate independent and local ethics
committees. Written, informed consent
was obtained for all patients before inclu-
sion in the study. Details of the study
design and methods of the OPTIMISE
study and the baseline results have been
reported previously (15,16).
In summary, investigators from six
European countries (Belgium, Greece,
Luxembourg, Portugal, Spain, and the
U.K.) were selected if they had sufﬁcient
patients with type 2 diabetes in treatment
in their practices and if they were willing
to fulﬁll the administrative procedures
linked to the study. Participating inves-
tigators were selected from general prac-
titioner or hospital-based outpatient
clinics to represent country-speciﬁc di-
abetes management practices. Outpa-
tients previously diagnosed with type 2
diabetes and $18 years of age were eligi-
ble for inclusion. Type 2 diabetes was di-
agnosed if, in two separate blood samples
taken on different days, fasting plasma
glucose was$126 mg/dL or 2-hour post-
load plasma glucose was $200 mg/dL.
Patients with gestational diabetes, pa-
tients with type 1 diabetes, those who
were hospitalized as a result of their di-
abetes, participants in other clinical trials,
and members of the Belgian Diabetes
Convention (a quality assurance program
with benchmarked feedback) were ex-
cluded. Between 10 and 20 patients per
physician were enrolled after assessment
for eligibility. Investigators were random-
ized by a centralized randomization pro-
cedure (What Health, Brussels, Belgium)
to either a benchmarking group or a con-
trol group. Randomization took place in a
1:1 ratio in Belgium (where the study
originated); some centers recruited 15–
20 patients, rather than the expected 8–
12 patients, which allowed a 3:1 random-
ization ratio in the other participating
countries. All patients enrolled by a given
investigator were included in the same
group. The sequence was concealed until
the intervention was assigned, and inves-
tigators were blinded to group assign-
ment. Because randomization was at the
investigator level, blinding of patients was
not applicable. The study was actively
monitored by external quality control au-
ditors. The ﬁrst study visit was on 6
March 2008, and the last visit was on 1
February 2010.
The study aimed to assess the impact
of benchmarking on the quality of primary
care for patients with type 2 diabetes. The
primary objective was to compare the
percentages of patients in the benchmark-
ing and control groups achieving preset
targets of the three critical modiﬁable
quality indicators for long-term microvas-
cular and macrovascular risk (HbA1c, LDL
cholesterol, and systolic BP [SBP]) after 12
months of follow-up. Secondary objec-
tives included determining the percentage
of patients achieving the preset targets in
comparison with baseline; percentage im-
provement in the preset targets versus
baseline, and follow-up of potential mark-
ers of preventive screening, such as reti-
nopathy, neuropathy, dietary counseling,
microalbuminuria, smoking habits, BMI,
and physical activity. An exploratory ob-
jective was to measure 10-year absolute
fatal cardiovascular risk in patients at
baseline and after 12 months of follow-
up according to the European Systematic
COronary Risk Evaluation (SCORE) risk
calculator estimated for low-risk and
high-risk countries (17,18).
The physicians in the study contin-
ued with the routine monitoring, treat-
ment, and counseling of their patients
with type 2 diabetes. There was no spe-
ciﬁc drug treatment recommended to be
used. Any medication considered neces-
sary for the patients was given at the
discretion of the investigator. Every 4
months, fasting blood samples were
taken, and HbA1c, glycemia, total choles-
terol, HDL cholesterol, LDL cholesterol,
and triglycerides were determined. All
blood samples were analyzed at a central
laboratory (Bio Analytical Research Cor-
poration, Ghent, Belgium). Further de-
tails of these tests have been previously
published (15). Both the benchmarking
and control groups received these labora-
tory results. The benchmarking proce-
dure comprised feedback given to each
investigator regarding the level of control
of the preset targets of their patients (15).
This information was provided every 4
months at the study visits and was anon-
ymously compared with results from
colleagues in the same country. The tar-
gets for the critical quality indicators were
#7% (53.0 mmol/mol) for HbA1c, ,100
mg/dL for LDL cholesterol, and ,130
mmHg for SBP (or ,125 mmHg in pa-
tients with proteinuria). A stricter target
value for LDL cholesterol (,80 mg/dL)
was adopted in Belgium by the National
Steering Committee.
Statistical analyses
SBP has been previously determined to be
the most critical quality indicator to bring
to target level and was therefore used as
the main item considered for the sample
size calculation. Full details have been
reported previously (15). It was assumed
from the results of the Belgian Evaluation
of Screening and Treatment of high-risk
patients based on waist and age (BEST)
study (19) that during the course of the
study a relative improvement of 88.7%
could be expected for the proportion of
patients with SBP control in both groups
(from 12.3 to 23.2%). It was also assumed
that benchmarking could improve the
level of SBP control by a further relative
32% (from 23.2 to 30.6%). Patients were
randomized at the physician level because
physicians’ individual approaches in dia-
betes management were expected to dif-
fer, which would result in an investigator
or cluster effect. A cluster effect from 5 to
10%, corresponding to an intracluster
correlation coefﬁcient of 0.05 to 0.10
(20–22), was taken into account. For an
intracluster correlation coefﬁcient of 0.05
(20 patients per physician), the cluster
randomization power analysis indicated
that a sample size of 3,000 in the bench-
marking group and 1,000 in the control
group would achieve 93% power to
detect a difference of 74% between the
groups (P = 0.05) with an unpooled,
two-sided z test.
Descriptive statistics of primary and
secondary variables were calculated on
the set of all evaluable patients (compris-
ing all patients who fulﬁlled the inclusion
criteria and who had completed the ﬁnal
visit at database lock). Categorical values
were described by frequency distribution.
Because in this study the physicians,
rather than individual patients, were ran-
domized, the data from the patients
recruited by each physician can be con-
sidered to form a cluster. Comparisons for
the primary and secondary variables were
carried out by multilevel mixed modeling
with the SAS procedure GLIMMIX for
categorical variables and the SAS proce-
dure MIXED for quantitative variables
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(SAS Institute Inc., Cary, NC). Differences
between data were considered signiﬁcant
at P , 0.05. The following confounder
variables were included in themixedmod-
els: treatment group, country, physician,
and interactions among these variables.
Because the randomization was done by
the physician, a random factor was incor-
porated to account for clustering of pa-
tients within individual physician’s
patient groups in each country. Visit num-
ber (1,4) was used as two time points in
the models to compare the frequencies of
reaching the target at baseline and at
month 12.
For the comparison of the two treat-
ment groups at month 12, the following
potential prognostic factors were consid-
ered: 1) For the analysis of SBP target, fac-
tors were treatment group, country, sex,
age, European SCORE risk, SBP, and the
number of antihypertensive treatment
classes used at baseline. 2) For the analysis
of HBA1c target, factors were treatment
group, country, sex, age, European SCORE
risk, HBA1c, and the number of glucose-
lowering drug classes used at baseline. 3)
For the analysis of LDL cholesterol target,
factors were treatment group, country,
sex, age, European SCORE risk, LDL cho-
lesterol value, and the number of lipid-
lowering classes used at baseline.
An interim analysis was carried out to
provide data for the baseline results,
which are presented elsewhere (16). The
number of patients in this ﬁnal analysis
was slightly larger than for the interim
analysis because of late veriﬁcation of col-
lection of informed consent.
RESULTSdBetween March and
December 2008, a total of 4,027 patients
were enrolled by 477 primary care physi-
cians from Belgium, Greece, Luxembourg,
Portugal, Spain, and the U.K. Of all
investigators, 293 were allocated to
the benchmarking group and 184 to
the control group. Of the 4,027 enrolled
patients, 31 patients were excluded. The
remaining 3,996 patients were evaluable,
and 3,487 (87.3%) completed 12 months
of follow-up (Fig. 1).
Baseline demographic and disease
characteristics were similar between
groups (16). Mean (SD) age of patients
was 65.6 (10.7) years in the benchmark-
ing group and 65.6 (11.0) years in the
control group. In the benchmarking
group, 54.8% were male, versus 55.2%
in the control group, and the mean (SD)
known duration of diabetes was 8.1 (7.5)
years, versus 8.0 (6.9) years. The fre-
quency and dosage of statin use were sim-
ilar in both groups at baseline and did not
notably change throughout the study
(Table 1). Neither were there substantial
changes in the number of patients taking
antihypertensives, glucose-lowering drugs,
lipid-lowering drugs, or aspirin between
the benchmarking and control groups dur-
ing the course of the study (Table 1). In-
tensity of treatment, indicated by the
number of drug classes taken, was similar
in both groups, with a trend toward an in-
creasing number of classes throughout the
study period (Table 1).
Mean (SD) HbA1c improved in the
benchmarking group from 7.2% (1.4%)
at baseline to 6.9% (1.5%) at 12 months
(55.7 [13.9] mmol/mol to 52.8 [12.8]
mmol/mol) and in the control group from
7.1% (1.3%) to 6.9% (1.2%) (54.4 [13.5]
mmol/mol to 51.8 [12.6] mmol/mol).
Baseline percentages of patients achieving
HbA1c target differed signiﬁcantly be-
tween the two groups (Fig. 2A). The per-
centage of patients achieving HbA1c target
signiﬁcantly increased from baseline to
12 months (secondary end point) in
both benchmarking (49.2–58.9%; P ,
0.001) and control groups (55.0–62.1%;
P, 0.001), with a greater increase in per-
centage of patients reaching the HbA1c
target in the benchmarking group. The
difference in the percentage of patients
in the benchmarking group in compari-
son with the control group achieving the
HbA1c target after 12months of follow-up
(primary end point) was not signiﬁcant
(58.9% [1,250/2,124] vs. 62.1% [846/
1,363]; P = 0.398) (Fig. 2A). In addition,
when baseline patient characteristics
where considered in the analysis, allo-
cation to the benchmarking group was
not a signiﬁcant predictor for achieving
the HbA1c target at 12 months, whereas
female sex (P = 0.008), lower HbA1c at
baseline (P , 0.001), and fewer glucose-
lowering drug classes (P, 0.001) were all
associated with a higher probability of
achieving the HbA1c target at 12 months
(Supplementary Table 1).
Mean (SD) SBP improved in the
benchmarking group from 138.0 (16.4)
mmHg at baseline to 133.0 (14.1) mmHg
at 12 months and in the control group
from 138.0 (17.0) mmHg to 135.7 (16.0)
mmHg. SBP was the least well-controlled
critical quality indicator at baseline, with
only 27.3% of patients at target in the
benchmarking group and 27.1% in the
control group. The percentage of patients
achieving the SBP target signiﬁcantly in-
creased from baseline to 12 months (sec-
ondary end point) in both benchmarking
(27.3–40.0%; P , 0.001) and control
(27.1–30.1%; P = 0.043) groups. A signif-
icantly higher percentage of patients had
reached the SBP target in the benchmark-
ing group than in the control group afterFigure 1dPatient disposition.
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12 months of follow-up (primary end
point, 40.0 vs. 30.1%; P , 0.001) (Fig.
2B). When baseline patient characteristics
where considered in the analysis, alloca-
tion to the benchmarking group was asso-
ciated with a 91% higher chance of
achieving the SBP target at 12 months
(P , 0.001). Older age at baseline was
also associated with a higher probability
of achieving the SBP target at 12 months
(0.008 for age at baseline), whereas higher
SBP, higher European SCORE Risk and
the number of antihypertensive drug clas-
ses used at baseline were associated with a
lower probability of achieving the SBP tar-
get at 12 months (P = 0.004 for SBP at
baseline, ,0.001 for European SCORE
Risk, and 0.04 for number of antihyper-
tensive drug classes used at baseline) (Sup-
plementary Table 1).
Mean (SD) LDL cholesterol improved
in the benchmarking group from 104.2
(34.2) mg/dL at baseline to 92.2 (32.4)
mg/dL and in the control group from
103.9 (34.1) mg/dL to 96.9 (32.8) mg/dL.
Patients with coronary heart disease
(CHD) generally had lower mean LDL
cholesterol at baseline than did patients
without CHD (94.5 vs. 106.5 mg/dL in
the benchmarking group and 91.3 vs.
106.9 mg/dL in the control group (17).
The percentage of patients reaching the
LDL cholesterol target signiﬁcantly in-
creased from baseline to 12 months (sec-
ondary end point) in both benchmarking
(from 40.8 to 54.3%; P, 0.001) and con-
trol (from 41.4 to 49.7%; P , 0.001)
groups. A signiﬁcantly higher percentage
of patients in the benchmarking group
than in the control group had reached
the LDL cholesterol target after 12
months of follow-up (primary end point,
54.3 vs. 49.7%; P = 0.006) (Fig. 2C).
When baseline patient characteristics
where considered in the analysis, alloca-
tion to the benchmarking group was as-
sociated with a 22.8% higher chance of
achieving the LDL cholesterol target at
12 months. Other signiﬁcant predictors
for achieving LDL cholesterol target at
the end of follow-up were female sex,
lower LDL cholesterol at baseline. and
younger age at baseline (P , 0.05 for
all) (Supplementary Table 1). The de-
crease in LDL cholesterol throughout
the study period was greater in patients
without CHD (the group with the higher
LDL cholesterol at baseline). In the
benchmarking group, LDL cholesterol
decreased by27.9 and211.3 mg/dL, re-
spectively, in patients with and without
CHD, and in the control group by
24.3 vs. 27.7 mg/dL.
The percentage of patients reaching
the targets for all three critical quality
indicators more than doubled in the
benchmarking group during 12 months
of follow-up (from 5.2 to 12.5%), com-
pared with a smaller increase in the
control group (from 5.7 to 8.1%) (Fig.
2D). The percentage of patients reaching
all three targets was signiﬁcantly larger in
the benchmarking group than in the con-
trol group (12.5 vs. 8.1%; P , 0.001).
Markers of preventive screening, such
as retinopathy, neuropathy, dietary coun-
seling, microalbuminuria, smoking hab-
its, BMI, and physical activity, showed no
substantial changes throughout the study
(Table 2). The 10-year risk of fatal cardio-
vascular disease as assessed by the mean
risk SCORE decreased in the benchmark-
ing group throughout the study (from
5.41 to 5.02), whereas this risk did not
decrease in the control group (from 5.49
to 5.50) (Supplementary Figure 1).
CONCLUSIONSdMeeting multiple
therapeutic targets with time remains an
important goal in the effective manage-
ment of type 2 diabetes. The baseline rates
of the predeﬁned target achievement re-
ported in OPTIMISE, however, show (16)
that these remain suboptimal. Recent sur-
veys of glycemic control (23) conﬁrm this
ﬁnding, and many studies have reported
difﬁculty in achieving this clinical objec-
tive (24–26). Given the increasing preva-
lence of type 2 diabetes, it is crucial from
both a clinical and cost burden perspec-
tive that improvedmanagement strategies
for type 2 diabetes be identiﬁed and im-
plemented. These strategies must also aim
to overcome the many barriers associated
with chronic disease management
(16,27). The current effort sought to ex-
plore in a randomized, controlled study
whether benchmarking could have an im-
pact on care of patients with type 2 dia-
betes in the primary care setting by
improving rates of target achievement
for the three paramount cardiovascular
risk factors.
For the primary end point, the per-
centage of patients reaching each of the
HbA1c, SBP, and LDL cholesterol targets
showed a greater increase during the
12-month follow-up period in the bench-
marking group than in the control group.
The observed increases in both groups
Table 1dMedications used at baseline and 12 months: antihypertensives, glucose-lowering,
lipid-lowering, and aspirin (evaluable patients)
Benchmarking Control
Baseline 12 months Baseline 12 months
Patients taking concomitant drugs
Antihypertensives 96.9 97.3 96.2 97.2
Glucose-lowering drugs 92.1 93.4 94.7 95.2
Lipid-lowering drugs 68.1 76.4 64.0 70.1
Aspirin 47.0 56.1 47.8 57.1
Number of classes of drug taken
Antihypertensive classes
0 24.8 24.7 26.2 25.2
1 25.2 22.0 24.6 23.9
2 26.2 27.1 27.4 24.7
3 17.2 18.5 15.8 18.9
.3 6.5 7.7 5.9 7.4
Glucose-lowering classes
0 8.2 6.8 5.5 4.8
1 45.3 42.0 47.3 45.2
2 38.3 40.7 40.0 40.7
3 7.5 10.0 7.3 8.7
.3 0.7 0.5 0.5 0.7
Lipid-lowering classes
0 32.1 23.6 36.0 29.9
1 62.8 69.1 59.6 65.6
2 4.9 7.0 4.2 4.1
3 0.1 0.3 0.2 0.4
All data are %.
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were signiﬁcant for SBP and LDL choles-
terol, whereas the percentage of patients
reaching HbA1c targets after 12 months
was not signiﬁcantly different. The per-
centage of patients achieving all three
targets increased during the study in
both groups; however, the absolute in-
crease in the percentage of patients
(7.3%) reaching all three targets from
baseline to 12 months in the benchmark-
ing group was three times that in the con-
trol group (2.4%). This is a meaningful
improvement, given that the proportion
of patients achieving all three targets at
the beginning of the study was low.
Such a small percentage of patients meet-
ing all three targets at baseline was not
unexpected, because the three critical
quality indicators have different phys-
iological mechanisms, show variable
degrees of worsening with time, and re-
spond differently to speciﬁc drugs and
lifestyle interventions. These results are
of clinical signiﬁcance, because in chronic
care even a stabilization of HbA1c is gen-
erally considered a success, particularly
if this is achieved without the use of ag-
gressive interventions as in this study. Be-
cause levels of each modiﬁable target are
normally distributed among patients with
diabetes, determining the proportion of
patients achieving all three targets, irre-
spective of the overall magnitude of the
ﬁgure, may represent an easy means to
estimate overall target achievement in a
cohort with diabetes and also its potential
improvement following an intervention.
At baseline, the percentage of patients
at target was lowest for SBP; SBP also had
the greatest increase in the percentage
achieving the target between the bench-
marking and control groups at 12 months
(P , 0.001). Similarly, the proportion of
patients achieving the LDL cholesterol
target at month 12 was signiﬁcantly
higher in the benchmarking group than
in the control group (P = 0.006). One pos-
sible explanation for the high SBP and
LDL cholesterol target achievement in
the benchmarking group could be the
overcoming of clinical inertia in response
Figure 2dPercentages of patients reaching critical quality indicator targets at baseline and after 12 months of follow-up. A: HbA1c target,7.0%
(,53.0 mmol/mol). B: SBP target,130 mmHg (,125 mmHg in patients with proteinuria). C: LDL cholesterol target,100 mg/dL (,80 mg/dL in
Belgium; ,70 mg/dL in patients with existing CHD). D: Percentages of patients reaching target for all three critical quality indicators.
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to high SBP or LDL cholesterol levels (i.e.,
physician failure to initiate or intensify
therapy when levels were not meeting tar-
get levels) (28). Feedback on the compar-
ison of a physician’s performance with
performance of other professionals and
accepted guidelines could represent an
intellectual, emotional, and competitive
stimulus for changes in the management
of a disease (15). The proportion of pa-
tients on antihypertensive and lipid-
lowering drugs did not increase during
the study period, and the numbers of
drug classes taken by patients during the
study period remained similar. No infor-
mation was collected on the daily dose
used for any of the drugs at baseline or at
study end. Benchmarked feedback may
therefore have been associated with treat-
ment intensiﬁcation in terms of increasing
daily dose of at least one drug, switching
to a different drug in the same therapeutic
class (with a higher bioequivalent dose
compared with the previous agent), or
increasing the frequency with which a pa-
tient received information on diet and
physical exercises.
Observational studies have shown
that clinical inertia in the management
of diabetes and its comorbidities, in terms
of physicians’ failure to intensify therapy,
is more likely to be observed for patients
with high BP and lipid levels than in cases
of poor glycemic control (29,30). This
could at least partly explain the relatively
good average glycemic control observed
in the OPTIMISE study at baseline in both
groups. Additionally, a slightly higher
percentage of patients were achieving
HbA1c targets at baseline in the control
group than in the benchmarking group.
This may explain the lack of signiﬁcant
improvement in the percentage of patients
reaching HbA1c targets after 12 months in
the benchmarking group relative to the
control group. With a mean diabetes dura-
tion of 8 years, it is unlikely that the rela-
tively low baseline HbA1c was secondary to
short disease duration and limited deterio-
ration of b-cell function at study entry;
however, one cannot rule out that some
physicians may have enrolled patients
with satisfactory glycemic control at base-
line. For Belgium, the exclusion of pa-
tients enrolled in the Belgian Diabetes
Convention, a quality assurance program
with benchmarked feedback, could rep-
resent another factor explaining the low
HbA1c values at enrollment. This pro-
gram enrolls patients with diabetes who
are receiving multiple daily insulin injec-
tions, and they often have long history of
diabetes, markedly reduced residual
b-cell function, and higher HbA1c values.
Another possible explanation is that,
in contrast to LDL cholesterol, HbA1c lev-
els tend to rise with time. This increase in
HbA1c, which is due to a natural patho-
physiological process of relentless loss of
residual insulin secretion, may account
for an increase in HbA1c as great as 0.3%
per year in some patients (31). Taking this
into account, the study duration of 12
months may not have been long enough
to generate a sizeable intensiﬁcation in
glucose-lowering agents to compensate
for the progressive b-cell function loss
with time.
The increased frequency of visits to
the physician may also be a contributory
factor, especially because this was expe-
rienced by both groups as a result of the
design of the study. HbA1c, BP, and LDL
cholesterol targets were recently reported
to be achieved faster when patients with
diabetes visited their primary care pro-
vider more frequently (32), whereas a
cross-sectional observational study of pa-
tients with type 2 diabetes identiﬁed less
frequent medical visits as an independent
determinant of inadequate glycemic con-
trol (33). Increasing the frequency of phy-
sician visits may provide a necessary
reminder for better adherence to lifestyle
modiﬁcations as well as pharmacological
treatments and thus may lead to improved
outcomes in SBP and LDL cholesterol man-
agement. Low patient adherence remains a
major factor that inﬂuences the achieve-
ment of positive clinical outcomes (34–
36). In addition, for the benchmarking
group, increasing the frequency of visits
combined with feedback on performance
could represent an opportunity to intensify
antihypertensive and lipid-lowering
treatments and to provide additional pa-
tient education.
As part of the exploratory analysis of
the study, changes in a number of poten-
tial markers of preventive screening were
Table 2dEvolution of potential markers of preventive screening: vital signs, laboratory data,
preventive examinations, and hygiene and lifestyle variables
Benchmarking Control
Characteristic Baseline 12 months Baseline 12 months
Vital signs
BMI (kg/m2) 30.4 (5.3) 30.2 (5.4) 30.5 (5.4) 30.1 (5.2)
Waist circumference (cm) 104.3 (13.9) 102.6 (13.8) 103.8 (13.3) 102.6 (13.3)
Diastolic BP (mmHg) 79.2 (9.2) 76.8 (8.4) 79.1 (8.9) 78.0 (8.8)
Laboratory data
Fasting glycemia (mg/dL) 141 (45.8) 140 (46.7) 140 (46.2) 141 (49.2)
HDL cholesterol (mg/dL) 48.9 (13.6) 49.9 (13.9) 49.7 (14.1) 50.9 (14.9)
Total cholesterol (mg/dL) 184.8 (39.8) 173.3 (38.0) 185.1 (40.7) 178.9 (38.7)
Triglycerides (mg/dL) 161.4 (93.1) 158.1 (114.6) 158.3 (89.8) 159.1 (101.9)
Microalbuminuria (mg/L) 53.9 (228.7) 48.4 (235.0) 60.0 (238.8) 56.6 (229.6)
Preventive examinations
Foot examination* 52 49 40 37
Ophthalmological
examination* 62 36 53 28
Needs assessment for
aspirin 64 61 64 62
Hygiene and lifestyle
Smoking status
Smoker 16 15 15 15
Dietary advice 84 74 78 65
Physical activity (optional)
No weekly activity 22 17 25 18
Light activity, most weeks 56 58 52 55
Heavy activity†,
1–2 times/week 13 16 14 16
Heavy activity†,
$3 times/week 9 8 9 11
Data are mean (SD) or %. *Baseline measurements refer to the previous 12months. Measurements during the
study refer to time since previous visit (previous 4 months). †Heavy physical activity causing shortness of
breath, increased heart rate, and perspiration.
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recorded, though without provision of
speciﬁc targets or benchmarked feedback.
No substantial changes were observed in
these markers; however, it is possible that
the study duration of 12 months was not
sufﬁcient to see any major changes.
The use of benchmarking to improve
achievement of critical quality indicators
during 12 months in patients with type 2
diabetes in primary care was found to be
effective for two of the critical quality
indicators, SBP and LDL cholesterol. This
improvement is consistent with the re-
sults of a small randomized, controlled
trial of benchmarking in diabetes primary
care (12). Benchmarking to improve clin-
ical outcomes has been tested in other
areas, such asmyocardial infarction, hyper-
tension, breast cancer screening, antibiotic
use, and immunization. Meta-analyses of
studies that have used benchmarking of
physicians providing health care to im-
prove the quality of care have reported
that effects vary from apparently negative
to very strongly positive but overall are gen-
erally small to moderate (37,38). They also
suggested that benchmarking effects are
likely to be larger where baseline compli-
ance with recommended practice is low
(37), which may have been a feature of
OPTIMISE given that the reported per-
centages of achievement of the vascular
risk targets at the start of the study were
low. The aspects of benchmarking that are
key to its effectiveness have not yet been
identiﬁed because of the small number of
studies conducted (37).
Limitations of this study included
estimation of LDL cholesterol levels by
the Friedewald formula (when triglycer-
ides were,400 mg/dL) rather than direct
measurement; however, this process re-
ﬂects clinical practice. In addition, the
history of proteinuria may have been un-
derestimated from reports in patient re-
cords because it was not routinely
tested. Another limitation is that the ex-
clusion of other forms of diabetes was
based solely on medical history. Thus pa-
tients with maturity-onset diabetes of the
young or other speciﬁc types of diabetes
may have been erroneously diagnosed as
having type 2 diabetes and enrolled in this
study. It should also be noted that our
conclusions only apply for a 12-month
period, and effects may not necessarily
persist through longer periods of bench-
marking. In addition, guidelines and tar-
gets may vary with time. The 12-month
study duration was, however, both long
enough to observe increases in target
achievement and short enough to ensure
consistency of targets with time and
among practices. Finally, the frequency
of visits made by the patients in both the
benchmarking and control groups may
have positively inﬂuenced outcomes in
both the groups. A Hawthorne effect
(39,40) may have occurred, whereby pa-
tients’ awareness that their HbA1c, SBP,
and LDL cholesterol were being moni-
tored caused them to improve adherence
to medication and lifestyle recommenda-
tions. It should be noted that the cardio-
vascular risk SCORE calculator is not
recommended for people with type 2 di-
abetes; however, instruments speciﬁc for
type 2 diabetes, such as the UK Prospec-
tive Diabetes Study Group Risk engine,
require further information that was not
collected in this study.
In conclusion, benchmarking as an
intervention to improve rates of target
achievement across the vascular risk fac-
tors HbA1c, SBP, and LDL cholesterol sig-
niﬁcantly increased target achievement in
SBP and LDL cholesterol relative to the
control group after 12 months of follow-
up. This approach is a promising tool for
improving the quality of care with respect
to disease management in type 2 diabetes.
This concept should be further evaluated
in the primary care setting.
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